Imidazopyrimidine modified naphthalimide-polyamine conjugate as well as preparation method and application thereof
The invention belongs to the technical field of compound synthesis, and particularly relates to an imidazopyrimidine modified naphthalimide-polyamine conjugate as well as a preparation method and application thereof. The imidazopyrimidine modified naphthalimide-polyamine conjugate is a compound shown in a formula I or a pharmaceutically acceptable salt thereof: # imgabs0 #. According to the invention, an imidazopyrimidine group is adopted to modify a 6-site of a naphthalimide naphthalene ring for the first time to synthesize a new imidazopyrimidine modified naphthalimide pharmacophore, and the new imidazopyrimidine modified naphthalimide pharmacophore is conjugated with polyamine, so that the novel imidazopyrimidine modified naphthalimide-polyamine conjugate is obtained. The compound keeps the activity of a naphthalimide compound, also has the characteristics of an imidazopyrimidine compound, improves the biological activity of original molecules, improves the anti-tumor activity of target molecules, shows obvious inhibitory activity on proliferation of various tumor cells, and has a good application prospect. The compound has a good application prospect in development of novel antitumor drugs and antitumor lead compounds..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 09. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
WANG YUXIA [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-09, Last update posted on www.tib.eu: 2024-03-25, Last updated: 2024-03-29 |
|---|
| Patentnummer: |
CN117362297 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA001398881 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA001398881 | ||
| 003 | DE-627 | ||
| 005 | 20240329155819.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA001398881 | ||
| 035 | |a (EPA)CN117362297 | ||
| 035 | |a (EPA)89390299 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a WANG YUXIA |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Imidazopyrimidine modified naphthalimide-polyamine conjugate as well as preparation method and application thereof |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-09, Last update posted on www.tib.eu: 2024-03-25, Last updated: 2024-03-29 | ||
| 520 | |a The invention belongs to the technical field of compound synthesis, and particularly relates to an imidazopyrimidine modified naphthalimide-polyamine conjugate as well as a preparation method and application thereof. The imidazopyrimidine modified naphthalimide-polyamine conjugate is a compound shown in a formula I or a pharmaceutically acceptable salt thereof: # imgabs0 #. According to the invention, an imidazopyrimidine group is adopted to modify a 6-site of a naphthalimide naphthalene ring for the first time to synthesize a new imidazopyrimidine modified naphthalimide pharmacophore, and the new imidazopyrimidine modified naphthalimide pharmacophore is conjugated with polyamine, so that the novel imidazopyrimidine modified naphthalimide-polyamine conjugate is obtained. The compound keeps the activity of a naphthalimide compound, also has the characteristics of an imidazopyrimidine compound, improves the biological activity of original molecules, improves the anti-tumor activity of target molecules, shows obvious inhibitory activity on proliferation of various tumor cells, and has a good application prospect. The compound has a good application prospect in development of novel antitumor drugs and antitumor lead compounds. | ||
| 650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a GE XIAOLING |4 aut | |
| 700 | 0 | |a WANG ZHIHUA |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 09. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:09 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89390299/publication/CN117362297A1?q=CN117362297 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 09 |c 01 | ||